Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Oncology
Join Editorial Board Propose a Special Issue
Print ISSN: 1019-6439 Online ISSN: 1791-2423
Journal Cover
September 2013 Volume 43 Issue 3

Full Size Image

Cover Legend PDF

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
September 2013 Volume 43 Issue 3

Full Size Image

Cover Legend PDF

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Anti-apoptotic proteins and catalase-dependent apoptosis resistance in nickel chloride-transformed human lung epithelial cells

  • Authors:
    • Yu-Xiu Yang
    • Xiu-Ling Li
    • Lei Wang
    • Shuang-Yin Han
    • Yan-Rui Zhang
    • Poyil Pratheeshkumar
    • Xin Wang
    • Jian Lu
    • Yuan-Qin Yin
    • Li-Juan Sun
    • Amit Budhraja
    • Andrew J. Hitron
    • Song-Ze Ding
  • View Affiliations / Copyright

    Affiliations: Department of Internal Medicine, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Graduate Center for Toxicology, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
  • Pages: 936-946
    |
    Published online on: July 3, 2013
       https://doi.org/10.3892/ijo.2013.2004
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Chronic exposure to nickel compounds is associated with increased incidence of certain types of human cancer, including lung and nasal cancers. Despite intensive investigation, the oncogenic processes remain poorly understood. Apoptosis resistance is a key feature for tumor cells to escape physiological surveillance and acquire growth advantage over normal cells. Although NiCl2 exposure induces transformation of human lung epithelial cells, little information is available with regard to its molecular mechanisms, it is also not clear if the transformed cells are apoptosis resistant and tumorigenic. We explored the apoptosis resistance properties of nickel chloride‑transformed human lung epithelial cells and the underlying mechanisms. The results showed that transformed BEAS-2B human lung epithelial cells are resistant to NiCl2-induced apoptosis. They have increased Bcl-2, Bcl-xL and catalase protein levels over the passage matched non‑transformed counterparts. The mechanisms of apoptosis resistance are mitochondria‑mediated and caspase-dependent. Forced overexpression of Bcl-2, Bcl-xL and catalase proteins reduced NiCl2-induced cell death; siRNA‑mediated knockdown of their expression sensitized the cells to nickel-induced apoptosis, suggesting that Bcl-2, Bcl-xl and catalase protein expression plays a critical role in apoptosis resistance. Akt also participates in this process, as its overexpression increases Bcl-xL protein expression levels and attenuates NiCl2-induced apoptosis. Furthermore, transformed cells are tumorigenic in a xenograft model. Together, these results demonstrate that nickel-transformed cells are apoptosis‑resistant and tumorigenic. Increased expression of Bcl-2, Bcl-xL and catalase proteins are important mechanisms contributing to transformed cell oncogenic properties.

Introduction

Nickel is a ubiquitous environmental metal, widely used in industrial processes. Nickel compounds are important human carcinogens. Epidemiologically, chronic and professional exposure to nickel compounds is associated with increased incidence of certain human cancer, including lung and nasal cancers (1,2). Both the soluble and insoluble forms of nickel compounds are detrimental to health with the insoluble form possesses higher risk, such as nickel oxide and nickel subsulfide (3,4). In 1990, nickel is classified as established carcinogen to humans (group 1) by International Agency for Research on Cancer (IARC) (3,4).

Several mechanisms have been proposed for nickel-induced carcinogenesis. These include production of reactive oxygen species (ROS), induction of DNA damage (1,4), alteration of epigenetic changes such as histone modifications (5,6), disruption of cellular iron homeostasis (7), and activation of oncogenic pathways (8,9). Despite intensive investigation, the molecular features of nickel-induced oncogenic transformation, which are essential components in tumor initiation and progression, remain elusive.

Apoptosis (programmed cell death) is a key mechanism to maintain normal cell homeostasis, it removes cells that carry abnormal genetic information and keeps the functional integrity of organ or cell populations (10). Aberrant expression of anti-apoptotic protein is a common feature to many types of malignancy including lung, breast, prostate cancer, melanoma and leukemia. Their overexpression confers the cancer cells a growth advantage to escape from physiological surveillance and promote tumor formation (10,11). Recent studies also suggest that activation of oncogenic pathways mediate nickel chloride (NiCl2)-induced epithelial cell oncogenic transformation accompanied by enhanced Bcl-2, Bcl-xL protein expression (9).

Bcl-2, and Bcl-xL protein expression has been implicated in cancer and cell transformation (10,12), therefore, we hypothesized that their overexpression in transformed cells may lead to apoptosis resistance contributing to nickel-induced carcinogenesis. However, it is not clear if a metal compounds such as nickel might induce apoptosis resistance in transformed cells and the underlying molecular mechanisms, neither is it known if these cells are tumorigenic. Therefore, we investigated the role of Bcl-2, Bcl-xL and ROS scavenging enzyme in nickel-induced apoptosis resistance and the molecular mechanisms, which are necessary steps to understand nickel-induced carcinogenesis.

We demonstrate in this study that increased Bcl-2, Bcl-xL and ROS scavenging enzyme expression are important in conferring NiCl2-transformed BEAS-2B cell apoptosis resistance. The mechanisms are mitochondria-mediated and caspase-dependent. Transformed cells are also tumorigenic with accompanied oncogenic protein expression. The results characterize the oncogenic properties of nickel-transformed human lung epithelial cells and provide insight into nickel-induced carcinogenesis.

Materials and methods

Cell culture and reagents

Immortalized normal human bronchial epithelial cell line, BEAS-2B was purchased from American Type Culture Collection (ATCC, Manassas, VA). NiCl2-transformed BEAS-2B cells were isolated from soft agar by low dose NiCl2 exposure with BEAS-2B cells for 6 months (9). These cells showed anchorage-independent growth, proliferated faster, but were morphologically similar to normal BEAS-2B cells (9). BEAS-2B cells that stably express catalase (OriGene, Rockville, MD), Akt and dominant negative-Akt (DN-Akt) which is a kinase-dead (K179M) mutant, were generated by integration of catalase, wild-type Akt (Akt-C), DN-Akt expression vectors into BEAS-2B cells and selected with G418. Characterization of these cells has been described before (13,14). Tissue culture reagents were purchased from Gibco (Invitrogen, Carlsbad, CA). Cells were maintained in DMEM medium supplemented with 10% fetal bovine serum and antibiotics at 37°C in a humidified 10% CO2 incubator.

Nickel chloride (NiCl2) was purchased from Sigma Chemical Company (St. Louis, MO, USA). Polyclonal and monoclonal antibodies against phospho-Akt at Ser473 (#9275), phospho-Stat3 (#9145), Bcl-xL (#2764), catalase (#8841), HIF-1α (#3434), cleaved caspase-3 (#9661), cleaved caspase-7 (#9491), cleaved PARP (#9542), peroxiredoxin 1 (#8499) were purchased from Cell Signaling Technology (Danvers, MA). Bcl-2 was from Dako (Carpinteria, CA). SOD1 (sc-11407), SOD2 (sc-130345), β-actin (sc-47778), lamin A/C (sc-6215), Akt1 (sc-5298) and NF-κB p50 (sc-7178) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Assays for apoptosis

Apoptosis was determined by Annexin V/propidium iodide (PI) staining kit (BD Pharmingen, San Jose, CA). In some experiments, due to the expression of green fluorescence protein (GFP) interfering with Annexin V-FITC reading, a double stain apoptosis detection kit using Hoechst 33342/PI staining (GenScript, Piscataway, NJ) was chosen to replace Annexin V-FITC. Briefly, cells (1×106) treated with or without NiCl2 were collected and washed once with cold PBS, they were stained with 5 μl of Annexin V-FITC or Hoechst 33342 followed by 10 μl of PI (5 μg/ml) in binding buffer [10 mmol/l HEPES (pH 7.4), 140 mmol/l NaOH, and 2.5 mmol/l CaCl2] for 15 min at room temperature in dark. The apoptotic cells were determined using a Becton-Dickinson FACScan cytofluorometer. Both early apoptotic (Annexin V or Hoechst 33342-positive and PI-negative) and late apoptotic (Annexin V or Hoechst 33342-positive and PI-positive) cells were included in cell death determinations.

Western blot analyses

Cell lysates were collected in lysis buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate, and 1 μg/ml of aprotinin, leupeptin and pepstatin). Proteins (20 μg) were separated on 10% SDS polyacrylamide gels. Proteins were subsequently transferred from gel onto nitrocellulose membrane (Bio-Rad, Hercules, CA). Membranes were blocked for 1 h at room temperature in Tris-buffered saline plus 0.01% Tween-20 (TBS-T) in 5% non-fat dry milk (pH 7.4). Various antibodies were diluted at 1:1,000 in TBS-T with 5% non-fat dry milk solution, incubated with membrane at 4°C overnight and washed three times with TBS-T. The secondary antibody, horseradish peroxidase (HRP)-conjugated antibodies, diluted at 1:2,500 in TBS-T with 5% non-fat dry milk were incubated with membrane at room temperature for 2–3 h. Signal was detected with an enhanced chemiluminescence detection kit (Perkin Elmer Life Sciences, Boston, MA). In each experiment, either anti-β-actin or anti-lamin A/C antibody was reprobed to monitor protein loading. Image quantification was processed by ImageJ software (NIH, Rockville, MD). In some experiments, mean densitometry values were adjusted with β-actin and expressed as fold changes over the appropriate controls.

Quantitative RT-PCR for gene expression

Total RNA from BEAS-2B cells was extracted using TRIzol reagents as described previously (15). Reverse transcription of 2 μg of total cellular RNA was performed in a final volume of 20 μl containing 5X first strand buffer (Invitrogen), 1 mM of each dNTP, 20 units of placental RNase inhibitor, 5 μM random hexamer and 9 units of Moloney murine leukemia virus reverse transcriptase (Invitrogen). After incubation at 37°C for 45 min, the samples were heated for 5 min at 92°C to end the reaction, diluted at 1:4 and stored at −20°C until PCR. cDNA (2 μl) was subjected to real-time quantitative PCR using the real-time PCR detection systems (Bio-Rad, Hercules, CA) with SYBR-Green I (Molecular Probes, Eugene, OR) as a fluorescent reporter. Threshold cycle number of duplicate reactions was determined using PCR software and levels of selected gene mRNA expression were normalized to hypoxanthine phosphoribosyltransferase (HPRT) levels using the formula 2(Rt-Et); where Rt is the mean threshold cycle for the reference gene HPRT and Et is the mean threshold cycle for experimental gene. Data are expressed as arbitrary units and adjusted to fold changes over the non-stimulated control cells. Primer sequences are provided in Table I.

Table I

PCR primers.

Table I

PCR primers.

Gene nameFor RT-PCR (5′→3′)
Bcl-2Fwd: GCCTTCTTTGAGTTCGGTGG
Rev: ATCTCCCGGTTGACGCTCT
Bcl-xLFwd: GAGCTGGTGGTTGACTTTCTC
Rev: TCCATCTCCGATTCAGTCCCT
HprtFwd: TTGGAAAGGGTGTTTATTCCTCA
Rew: TCCAGCAGGTCAGCAAAGAA

[i] Hprt, hypoxanthine phosphoribosyltransferase.

Measurement of mitochondrial membrane potential

Mitochondrial membrane potential (ΔΨm) was monitored using MitoProbe JC-1 assay kit (Invitrogen). 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1), a lipophilic cationic fluorescence dye, is capable of selectively entering mitochondria, where it forms monomers, and emits green fluorescence (FL-1) when ΔΨm is relatively low. At high ΔΨm, JC-1 aggregates and gives red fluorescence (FL-2) (16). Thus the red and green fluorescence of JC-1 reflect the change of ΔΨm of the mitochondrial membrane. Briefly, BEAS-2B or transformed BEAS-2B cells (5×105) were seeded into 60-mm culture dishes and treated with NiCl2 for 16 h. Cells were trypsinized, washed in ice-cold PBS and incubated with 2 μM JC-1 at 37°C for 20 min. Cells were washed once with PBS and analyzed by FACScan cytofluorometer.

Caspase activity assay

Caspase activity was assessed using the luminescent Caspase-Glo® 3/7 assay system (Promega, Madison, WI) following manufacturer’s instructions. Briefly, BEAS-2B or transformed BEAS-2B cells were treated with or without NiCl2 at 1.5 mM for 16 h. Caspase-Glo 3/7 reagent (100 μl) was added into 96-well plates and incubated for 1 h at room temperature. The luminescence was measured using a Glomax™ 96 microplate luminometer (Promega). Z-VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone), a cell-permeant pan-caspase inhibitor that irreversibly binds to the catalytic site of caspase proteases that inhibit induction of apoptosis was added 30 min before nickel stimulation at 20 μM solution in DMSO (Promega). Data were collected and expressed as fold change over the control without NiCl2 treatment.

Small interfering RNA transfection

Transfection procedures followed manufacturer’s recommended protocol. Small interference RNA (siRNA) for Bcl-2 (sc-29214), Bcl-xL (sc-43630) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Scrambled control and siRNA for catalase (s-2443) were obtained from Ambion (Austin, TX). Briefly, siRNA for Bcl-2, Bcl-xL, catalase and controls were incubated with Lipofectamine™ RNAiMAX in Opti-MEM I medium (Invitrogen) for 20 min at room temperature. They were then added to cell culture media without antibiotics. Media were replaced 24 h post-transfection. Cells were treated with or without NiCl2 for another 24 h. Cell lysates or cells were collected either for western blot or apoptosis analysis as mentioned above.

Retrovirus infection

GFP labeled p-MIG, p-MIG-Bcl-2, pMIG-Bcl-xL retroviral vector (17) were kind gifts from Dr Stanley Korsmeyer, Dana-Farber Cancer Institute, USA (Addgene, #9044, #3541, #3544). The plasmids were transfected into 293-GPG cell using Lipofectamine 2000 reagent, viruses were produced in 293-GPG cells with subsequent centrifugation, filtration and stored at −20°C. BEAS-2B or T-BEAS-2B cells were then infected with control, Bcl-2, Bcl-xL retroviruses by adding virus solution into the cells with polybrene for 48 h before they were used for apoptosis and western blot analysis, virus infection in cells was monitored by checking GFP under fluorescence microscope.

Tumor xenograft model

Athymic nude (nu/nu) female mice, 5 weeks old and weighing about 18 to 20 g were purchased from Jackson Laboratory (Bar Harbor, MI). Mice were handled following the University of Kentucky guidelines for care and use of laboratory animals and approved by the ethical committee. BEAS-2B or transformed BEAS-2B cells (2×106) were mixed with Matrigel and injected in both side of flank region in 50 μl volume. Five animals in each group gave 10 injection sites. Mice were fed normally, the body weight, and tumor growth was monitored twice weekly until the tumor size reached 1 × 1 × 1 cm3 in size or 8 weeks post inoculation.

Statistical analysis

All values are expressed as mean ± standard error (SEM). Student’s t-test was used to compare the difference between various controls and NiCl2-treated groups. P-value less than 0.05 was considered statistically significant.

Results

Transformed BEAS-2B cells have increased Bcl-2, Bcl-xL protein expression and are resistant to nickel-induced apoptosis

To evaluate Bcl-2, Bcl-xL protein expression and their role in nickel-induced apoptosis, BEAS-2B and transformed BEAS-2B (T-BEAS-2B) cells were first treated with or without 0.5, 1 and 1.5 mM of NiCl2 for 24 h for apoptosis induction. At 0.5, and 1 mM doses, only BEAS-2B cells showed apoptosis induction in 24 h, T-BEAS-2B cell showed little or no apoptosis (data not shown), therefore, 1.5 mM of NiCl2 was selected for apoptosis induction in both types of cells.

BEAS-2B and T-BEAS-2B cells were treated with or without 1.5 mM of NiCl2 for 24 h to analysis apoptosis. The results indicated that T-BEAS-2B cells had significantly lower level of apoptosis (Fig. 1A), but increased Bcl-2, and Bcl-xL protein expression (Fig. 1B and C) when compared with control BEAS-2B cells. Following NiCl2 exposure, the Bcl-2, and Bcl-xL protein expression declined in both type of cells, but control BEAS-2B cells had greater level of reduction than T-BEAS-2B cells (Fig. 1B and C). To understand if Bcl-2, and Bcl-xL protein reduction might be due to NiCl2-induced transcriptional repression, quantitative RT-PCR assay was performed in both types of cells. Fig. 1D shows that Bcl-2 and Bcl-xL mRNA expression was repressed in BEAS-2B cells following NiCl2-treatment. Similar pattern of mRNA expression was also noted in T-BEAS-2B cells (data not shown). These results suggested a mechanism of NiCl2-induced gene transcription repression (Fig. 1D).

Figure 1

Transformed BEAS-2B cells are resistant to nickel-induced apoptosis. BEAS-2B or transformed BEAS-2B (T-BEAS-2B) cells (1×106) were treated with or without 1.5 mM of NiCl2 for 24 h. (A) Apoptosis was analyzed from the treated cells by Annexin V/PI staining followed by flow cytometry analysis. (B) Cell lysates were collected and resolved in 10% SDS-PAGE to detect respective protein expression, arrows indicate the specific band. (C) Scanned densitometry data were expressed as arbitrary unit and adjusted as fold changes over the control. (D) Bcl-2 and Bcl-xL mRNA expression from the treated BEAS-2B cells were determined by real-time PCR as stated in Materials and methods. Data are mean ± SEM from 3–4 separate experiments. *P<0.05 when compared with control cells.

We tested if the levels of Bcl-2 and Bcl-xL protein expression in BEAS-2B and T-BEAS-2B cells might affect NiCl2-induced apoptosis. Forced overexpression of Bcl-2, and Bcl-xL protein with plasmids in BEAS-2B cells reduced NiCl2-induced cell apoptosis in a dose-dependent manner (Fig. 2A–C). In contrast, siRNA knockdown of Bcl-2, and Bcl-xL protein expression in T-BEAS-2B cells enhanced the apoptosis rate (Fig. 2A and D). These results suggested that the relative levels of Bcl-2, and Bcl-xL protein are important for apoptosis induction/resistance in both types of cells.

Figure 2

Effects of Bcl-2, and Bcl-xL expression in NiCl2-induced apoptosis. BEAS-2B cells were infected with control empty vector, Bcl-2, and Bcl-xL retrovirus (control, Bcl-2, Bcl-xL), transformed BEAS-2B cells (T-BEAS-2B) were transfected with control, Bcl-2, and Bcl-xL siRNA (siRNA). Cells were treated with or without NiCl2 at 0.75 and 1.5 mM for 24 h. To determine Bcl-2, and Bcl-xL specific protein expression, cell lysates were collected from the retrovirus infected and siRNA transfected cells (A). Protein (20 μg) was resolved in 10% SDS-PAGE to detect the respective protein expression. Blots are representative of 2–3 separate experiments with similar results, arrows indicate the specific band. Apoptosis was assayed using either Annexin V/PI (B and C) or Hoechst 33342/PI staining (D) followed by flow cytometry analysis. Data are mean ± SEM from three separate experiments, *P<0.05 when compared with controls.

Effects of catalase in NiCl2-induced apoptosis

After cell transformation, ROS generation is reduced in transformed cells, a mechanism that attributed to increased ROS scavenging enzyme expression (18). We examined if the apoptosis resistance in NiCl2-transformed cells are accompanied by higher ROS scavenging proteins expression. The results showed upregulation of catalase in nickel-transformed cells over the controls (Fig. 3A and B). Overexpression of catalase by using a stable cell line reduced NiCl2-induced apoptosis; in contrast, using catalase siRNA to reduce its expression (data not shown) enhanced apoptosis (Fig. 3C). These results suggested that catalase or generation of ROS is important mechanism in NiCl2-induced apoptosis. Western blot analysis also indicated that other ROS scavenging enzymes such as SOD2, and Prx-1 protein levels were increased in T-BEAS-2B cells when compared with control non-transformed BEAS-2B cells (Fig. 3D), while SOD1, and Phox47 protein expression showed no difference (data not shown). Thus, these results provide mechanistic explanation of reduced ROS level in T-BEAS-2B cells as reported previously (9), and these mechanisms may contribute to the apoptosis resistance in transformed cells.

Figure 3

Effects of catalase in NiCl2-induced apoptosis. BEAS-2B (B-2B), transformed BEAS-2B (T-BEAS-2B, T-B-2B) (1×106) were treated with or without NiCl2 at 1.5 mM for 24 h. Cell lysates were collected and resolved in 10% SDS-PAGE to detect catalase and other ROS scavenge proteins expression (A–C), blots are representative of 2–3 separate experiments with similar results. Arrows indicate the specific band. Densitometry data from catalase were scanned as arbitrary unit and adjusted as fold changes over the control (B). To determine the role of catalase in NiCl2-induced apoptosis (D), BEAS-2B (B-2B) cells were transfected with or without catalase siRNA (B-2B-Cat-siRNA) for 48 h. Cells were treated with or without NiCl2 at 1.5 mM for another 24 h. BEAS-2B catalase-stable expressing cells (Cat-stable) also received the same treatment. Apoptosis was assayed by Annexin V/PI staining followed by flow cytometry analysis (D). Data are mean ± SEM from three separate experiments, *P<0.05 when compared with control cells.

Transformed cells are resistant to NiCl2-induced mitochondria damage

To investigate whether transformed cells are resistant to mitochondria damage. We evaluated NiCl2-induced mitochondria damage in both types of cells and the role of Bcl-2 and Bcl-xL in these processes. The results showed that T-BEAS-2B cells are more resistant to NiCl2-induced mitochondrial damage compared with non-transformed BEAS-2B cells (Fig. 4A and B). Forced overexpression of Bcl-2, Bcl-xL and catalase largely abolished NiCl2-induced mitochondria damage in BEAS-2B cells (Fig. 4C and D). Significant difference was noted when the quantitative data were compared with control cells (*P<0.05). These results indicated that enhanced Bcl-2, Bcl-xL and catalase protein expression are important mechanisms for reduced mitochondria damage in transformed cells.

Figure 4

Transformed cells are resistant to NiCl2-induced mitochondria damage. To evaluate NiCl2-induced mitrochodria damage, BEAS-2B, transformed BEAS-2B (T-BEAS-2B), control empty vector, Bcl-2, and Bcl-xL-retrovirus infected BEAS-2B (control, Bcl-2, Bcl-xL) and BEAS-2B catalase-stable expressing cells (Cat-stable) (1×106) were treated with or without NiCl2 at 1.5 mM for 16 h. Cells were stained with JC-1 dye followed by flow cytometry analysis. (A and C) Representative images are shown; (B and D) quantification of three separate experiments are expressed as mean ± SEM. (B and D) *P<0.05 when compared with controls.

Caspase activation in nickel-transformed cells

The above results demonstrated that T-BEAS-2B cells differ from BEAS-2B cells in NiCl2-induced apoptosis resistance and mitochondria damage; thus we further studied the underlying molecular mechanisms. We compared caspase activation in both types of cells. The result in Fig. 5 clearly indicates that upon NiCl2 stimulation, BEAS-2B cells had much stronger caspase activation, presented as increased c-caspase 3, 7 and c-PARP protein expression when compared with T-BEAS-2B cells (Fig. 5A). This was accompanied by increased caspase 3/7 enzymatic activity, while Z-VAD, a pan-caspase inhibitor, blocked the caspase 3/7 enzymatic activity (Fig. 5B), reduced c-caspase 3, 7 expression (Fig. 5C), and attenuated apoptosis (Fig. 5D).

Figure 5

Caspase activation in nickel-transformed cells. BEAS-2B, transformed BEAS-2B (T-BEAS-2B), control empty vector, Bcl-2, and Bcl-xL-retrovirus infected BEAS-2B (Bcl-2, Bcl-xL) and BEAS-2B catalase-stable expressing cells (Cat-stable) (1×106) were treated with or without NiCl2 at 1.5 mM for 24 h. Cell lysate was collected and 20 μg of protein resolved in 10% SDS-PAGE to detect respective protein expression (A, C, E–G). Blots are representative from 3–4 separate experiments with similar results, arrows indicate the specific band. To determine caspase 3/7 enzymatic activity, BEAS-2B and T-BEAS-2B cells were treated with or without NiCl2 at 1.5 mM for 16 h and enzymatic activity was assayed as described in Materials and methods (B). For apoptosis assay, BEAS-2B, transformed BEAS-2B (T-BEAS-2B) cells were treated with or without NiCl2 at 1.5 mM and Z-VAD for 24 h, apoptosis was assayed using the Annexin V/PI staining followed by flow cytometry (D). Quantitative data are expressed as mean ± SEM from three separate experiments, *P<0.05 when compared with respective controls.

In addition, we evaluated if Bcl-2, Bcl-xL and catalase proteins that are overexpressed in T-BEAS-2B cell may antagonize the NiCl2-induced caspase activation. The results indicated that overexpression of Bcl-2, Bcl-xL and catalase protein effectively reduced the c-caspase 3, 7 and c-PARP protein expression (Fig. 5E–G), respectively, correlating with reduced mitochondria damage and apoptosis. Therefore, these results demonstrated that upregulation of Bcl-2, Bcl-xL and catalase in T-BEAS-2B suppresses caspase activation, which are essential mechanisms underlying the adapted apoptosis resistance in these cells.

Role of p-Akt in NiCl2 induced-apoptosis

p-Akt expression was upregulated in T-BEAS-2B cells in a previous study (9). To understand its role in NiCl2-induced apoptosis, we used Akt overexpression (Akt-C) and dominant negative Akt (DN-Akt) stable cell lines to determine the effects of Akt on NiCl2-induced apoptosis. The results indicated that Akt stable cells had persistently enhanced p-Akt level (Fig. 6A), and increased Bcl-xL protein expression, but not Bcl-2 expression; while in DN-Akt cells, Bcl-2, and Bcl-xL protein expression remain at the basal control level (Fig. 6A and B). In addition, NiCl2 challenge induced marginally higher levels of apoptosis in control and DN-Akt cells over the Akt stable cells (Fig. 6C), pointing out the protective roles of Akt in NiCl2-induce BEAS-2B cell apopotsis.

Figure 6

Effects of Akt expression in NiCl2-induced apoptosis. BEAS-2B and BEAS-2B stably expressing Akt (Akt-C), dominate negative-Akt (DN-Akt) cells were treated with or without NiCl2 at 1.5 mM for 24 h. Cell lysates were collected and 20 μg of protein was resolved in 10% SDS-PAGE to detect protein expression. Blots are representative of three separate experiments with similar results. (A) Arrows indicate the specific band. (B) Scanned densitometry data are expressed as arbitrary units and adjusted as fold changes over the control. (C) Apoptosis was determined by Annexin V/PI staining followed by flow cytometry analysis. Data are mean ± SEM from three separate experiments, *P<0.05 when compared with control cells.

Tumorigenic properties of NiCl2 transformed cells

To evaluate if the transformed cells are tumorigenic, we injected both control BEAS-2B and T-BEAS-2B cells into nude mice and observed the tumor growth. The results indicated that among five injected mice in each group, only T-BEAS-2B cells induced tumor growth, and tumors occurred at multiple injection sites, grew into various sizes within 8 weeks (Fig. 7A and B). Furthermore, western blot analysis revealed increased HIF-1α NF-κB-p50 subunit and p-Stat3 protein expression in T-BEAS-2B cells when compared with non-transformed cells, underlying the oncogenic features of the NiCl2-transformed cells (Fig. 7C).

Figure 7

Tumorigenic properties of NiCl2-transformed cells. BEAS-2B or transformed BEAS-2B (T-BEAS-2B) cells (2×106) were mixed with matrigel and injected subcutaneously into athymic nude mice on both sides of flank region. (A and B) Five animals were injected in each group, tumor growth were monitored twice weekly until the tumor size reach 1 × 1 × 1 cm3 in size or by 8 weeks post inoculation. (C) To monitor the oncogenic protein expression in transformed BEAS-2B cells, cell lysates from each type of cell were collected and resolved in 10% SDS-PAGE to detect p-Stat3, NF-κB-p50 subunit and HIF-1α protein expression. Blots are representative of 3–4 separate experiments with similar results. Arrows indicate the specific band.

Discussion

Nickel is a known human carcinogen and induces genotoxic stress. A number of mechanisms have been proposed for its carcinogenic effects; such as generation of ROS, induction of DNA damage, and activation of oncogenic pathways (3). However, little information is available with regard to the mechanisms of apoptosis resistance in nickel-transformed cells. In this study, we focused on apoptosis resistant and tumorigenic property of NiCl2-transformed human lung epithelial cells, and explored the potential molecular mechanisms. The results demonstrate that NiCl2 transformed BEAS-2B cells are resistant to apoptosis and tumorigenic. Higher levels of Bcl-2, Bcl-xL and catalase protein expression are important mechanisms contributing to the transformed cell oncogenic properties.

Previously in vitro studies have shown that water-insoluble nickel compounds such as nickel oxide, nickel subsulfide are more readily phagocytized than the water-soluble nickel compounds such as nickel chloride. They can reach the nucleus of the cell in greater amounts than that of water-soluble nickel compounds and induce more cell damage (19,20). In the current study, NiCl2 was selected due to the BEAS-2B cells being transformed by NiCl2 exposure (9). One important characteristic of nickel compounds is the generation of ROS in host cells, and ROS appear critical in nickel-induced cell damage, such as apoptosis and oncogenic transformation (1,4). Increasing evidence has indicated that ROS plays an important role in inducing apoptosis and carcinogenesis following diverse exposure to environmental stimuli (21). However, ROS generation in transformed cells is reduced (9,18), the mechanism is not clear. In the current study, we confirm that antioxidant enzymes are increased in transformed cells including catalase, SOD2 and Prx-1 (22), suggesting that they are responsible for the reduced ROS generation in transformed cells (9,18). Higher ROS scavenging enzyme expression may also contribute to NiCl2-induced apoptosis resistance in transformed cells by attenuating the detrimental effects from ROS generated by NiCl2 exposure. However, the biological implications of these changes during transformation have yet to be explored, as well as the molecular mechanisms that result in their increased expression in transformed cells. The data provide evidence that transformation involves multiple cellular signal alternations, which deserve further investigation.

Bcl-2 and Bcl-xL proteins are overexpressed in a variety of human cancers (23), and are important members of anti-apoptotic proteins family. The mechanisms of Bcl-2 and Bcl-xL protect cells from apoptosis through either heterodimerization with pro-apoptotic proteins, or their direct pore-blocking effects on the outer membrane of mitochondria (11,23). Mitochondria play a critical role in apoptosis induction, which involves both caspase-dependent and -independent pathways. We noted that NiCl2-induced apoptosis can be affected by both Bcl-2 and Bcl-xL expressing vector and siRNA transfection, indicating that their relative levels regulate cell apoptosis resistance in T-BEAS-2B cells. The question of how transformed cell evolve into higher level of Bcl-2, and Bcl-xL protein expression remain to be investigated, we hypothesis that either genetic or epigenetic modifications may be responsible during the transformation and selection processes.

In our study, NiCl2 treatment reduced the cellular level of Bcl-2 and Bcl-xL proteins in both transformed and non-transformed cells (Fig. 1A and B), but the level of reduction in transformed cells is less dramatic, which is associated with low apoptotic rate. This effect also correlates with reduced mitochondrial stress, c-caspase 3, 7 protein level, caspase enzymatic activity and PARP cleavage. Together, they suggest that transformed cells evolve a mechanism of increased Bcl-2/Bcl-xL protein expression, reduced mitochondrial stress and alleviated caspase activation upon NiCl2 exposure, therefore, confer these cells the apoptosis resistant property.

Several signaling pathways such as PI3K, NF-κB, Akt, and Sonic hedgehog have been shown to regulate Bcl-2 and Bcl-xL protein expression and apoptosis in different cell types (12,24,25). Induction of cyclooxygenesis 2 is also important in nickel induced apoptosis (26). In the current study, we focus on the effects of Bcl-2, Bcl-xL, and catalase by examining their roles in apoptosis resistance in transformed cells, as they are either the effector proteins downstream of the above mentioned signal pathways or involved in ROS generation. Akt is a serine/threonine kinase, also known as protein kinase B (PKB). It is involved in regulating multiple cellular functions, including cell growth, proliferation, survival, glucose metabolism and genome stability (27,28). Aberrant Akt activation has been noted in breast, prostate, lung, pancreatic, liver, ovarian and colorectal cancers, and in malignant transformation (27–30). Akt overexpression enhances Bcl-xL expression, which is correlated with the fact that Akt-stable expressing cells are more resistant to NiCl2-induced apoptosis. The results uncovered anti-apoptotic protein-dependent mechanism in nickel-induced apoptosis resistance in transformed cells.

It is worth noting that overexpression of Akt could not completely block the nickel-induced apoptosis (Fig. 6), and even this effect was marginal. Since there are two major apoptotic pathways, the death-receptor pathway and the mitochondrial pathway, we consider other signal pathways might also contribute to the nickel-induced apoptosis. It has been reported that increased FasL expression, cell cycle alteration, activation of c-Myc through ERK pathway, caspase-8/AIF-mediated pathways, and activation of NF-κB/Cox2 pathway all participate in nickel-induced apoptosis (26,31–34). Therefore, each may initiate and contribute to the pathway or cell type-specific apoptosis processes in additional to the mechanisms discussed in the present study. However, increased Bcl-2, Bcl-xL and catalase protein expression, reduced mitochondria damage and caspase activation described here appear to be the essential mechanisms involved in NiCl2-mediated cell death resistance program in transformed BEAS-2B cells. Future investigations will be required to clarify if other mechanisms might also be involved in transformed cell resistance to apoptosis.

One important feature of transformed cells is their tumorigenic property. These cells also have enhanced p-Stat3, NF-κB-p50 subunit, and HIF-1α protein expression. The altered oncogene expression probably reflects extensive genetic or epigenetic rearrangements during the transformation processes which allow transformed cells to adopt and grow in a new environment. It is also possible that they acquire cancer stem cell trait to allow cell resistant apoptosis. Future studies focusing on nickel-induced apoptosis resistance and cell transformation are of great interest to understand nickel-induced carcinogenic mechanisms and to provide options for prevention.

Acknowledgements

This research was supported in part by NIH grants (1R01CA119028) and a Henan provincial government bio-medical key research grant (132102310444).

References

1 

Costa M: Molecular mechanisms of nickel carcinogenesis. Annu Rev Pharmacol Toxicol. 31:321–337. 1991. View Article : Google Scholar

2 

Doll R, Morgan LG and Speizer FE: Cancers of the lung and nasal sinuses in nickel workers. Br J Cancer. 24:623–632. 1970. View Article : Google Scholar : PubMed/NCBI

3 

Costa M, Davidson TL, Chen H, et al: Nickel carcinogenesis: epigenetics and hypoxia signaling. Mutat Res. 592:79–88. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Lu H, Shi X, Costa M and Huang C: Carcinogenic effect of nickel compounds. Mol Cell Biochem. 279:45–67. 2005. View Article : Google Scholar

5 

Salnikow K and Zhitkovich A: Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem Res Toxicol. 21:28–44. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Salnikow K and Costa M: Epigenetic mechanisms of nickel carcinogenesis. J Environ Pathol Toxicol Oncol. 19:307–318. 2000.

7 

Davidson T, Chen H, Garrick MD, D’Angelo G and Costa M: Soluble nickel interferes with cellular iron homeostasis. Mol Cell Biochem. 279:157–162. 2005. View Article : Google Scholar : PubMed/NCBI

8 

Pan J, Chang Q, Wang X, et al: Reactive oxygen species-activated Akt/ASK1/p38 signaling pathway in nickel compound-induced apoptosis in BEAS 2B cells. Chem Res Toxicol. 23:568–577. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Pan JJ, Chang QS, Wang X, et al: Activation of Akt/GSK3β and Akt/Bcl-2 signaling pathways in nickel-transformed BEAS-2B cells. Int J Oncol. 39:1285–1294. 2011.

10 

Cory S and Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2:647–656. 2002. View Article : Google Scholar : PubMed/NCBI

11 

Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI

12 

Pugazhenthi S, Nesterova A, Sable C, et al: Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 275:10761–10766. 2000. View Article : Google Scholar : PubMed/NCBI

13 

Ding SZ, Yang YX, Li XL, et al: Epithelial-mesenchymal transition during oncogenic transformation induced by hexavalent chromium involves reactive oxygen species-dependent mechanism in lung epithelial cells. Toxicol Appl Pharmacol. 269:61–71. 2013. View Article : Google Scholar

14 

Zhou BP, Hu MC, Miller SA, et al: HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem. 275:8027–8031. 2000. View Article : Google Scholar : PubMed/NCBI

15 

Ding SZ, Fischer W, Kaparakis-Liaskos M, et al: Helicobacter pylori-induced histone modification, associated gene expression in gastric epithelial cells, and its implication in pathogenesis. PLoS One. 5:e98752010. View Article : Google Scholar

16 

Cossarizza A, Baccarani-Contri M, Kalashnikova G and Franceschi C: A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun. 197:40–45. 1993.PubMed/NCBI

17 

Cheng EH, Wei MC, Weiler S, et al: BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 8:705–711. 2001. View Article : Google Scholar : PubMed/NCBI

18 

Chang Q, Pan J, Wang X, Zhang Z, Chen F and Shi X: Reduced reactive oxygen species-generating capacity contributes to the enhanced cell growth of arsenic-transformed epithelial cells. Cancer Res. 70:5127–5135. 2010. View Article : Google Scholar

19 

Dunnick JK, Elwell MR, Radovsky AE, et al: Comparative carcinogenic effects of nickel subsulfide, nickel oxide, or nickel sulfate hexahydrate chronic exposures in the lung. Cancer Res. 55:5251–5256. 1995.PubMed/NCBI

20 

Oller AR, Costa M and Oberdorster G: Carcinogenicity assessment of selected nickel compounds. Toxicol Appl Pharmacol. 143:152–166. 1997. View Article : Google Scholar : PubMed/NCBI

21 

Zhao J, Shi X, Castranova V and Ding M: Occupational toxicology of nickel and nickel compounds. J Environ Pathol Toxicol Oncol. 28:177–208. 2009. View Article : Google Scholar : PubMed/NCBI

22 

Kim YJ, Ahn JY, Liang P, Ip C, Zhang Y and Park YM: Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res. 67:546–554. 2007. View Article : Google Scholar : PubMed/NCBI

23 

Yip KW and Reed JC: Bcl-2 family proteins and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Catz SD and Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 20:7342–7351. 2001. View Article : Google Scholar : PubMed/NCBI

25 

Bigelow RL, Chari NS, Unden AB, et al: Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem. 279:1197–1205. 2004. View Article : Google Scholar : PubMed/NCBI

26 

Ding J, Zhang X, Li J, et al: Nickel compounds render anti-apoptotic effect to human bronchial epithelial BEAS-2B cells by induction of cyclooxygenase-2 through an IKKbeta/p65-dependent and IKKalpha- and p50-independent pathway. J Biol Chem. 281:39022–39032. 2006. View Article : Google Scholar : PubMed/NCBI

27 

Lawlor MA and Alessi DR: PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 114:2903–2910. 2001.PubMed/NCBI

28 

Morley S, Wagner J, Kauppinen K, Sherman M and Manor D: Requirement for Akt-mediated survival in cell transformation by the dbl oncogene. Cell Signal. 19:211–218. 2007. View Article : Google Scholar : PubMed/NCBI

29 

Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI

30 

Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI

31 

Li Q, Suen TC, Sun H, Arita A and Costa M: Nickel compounds induce apoptosis in human bronchial epithelial Beas-2B cells by activation of c-Myc through ERK pathway. Toxicol Appl Pharmacol. 235:191–198. 2009. View Article : Google Scholar : PubMed/NCBI

32 

Ding J, He G, Gong W, et al: Effects of nickel on cyclin expression, cell cycle progression and cell proliferation in human pulmonary cells. Cancer Epidemiol Biomarkers Prev. 18:1720–1729. 2009. View Article : Google Scholar : PubMed/NCBI

33 

Kim K, Lee SH, Seo YR, Perkins SN and Kasprzak KS: Nickel(II)-induced apoptosis in murine T cell hybridoma cells is associated with increased fas ligand expression. Toxicol Appl Pharmacol. 185:41–47. 2002. View Article : Google Scholar : PubMed/NCBI

34 

Zhao J, Bowman L, Zhang X, et al: Metallic nickel nano- and fine particles induce JB6 cell apoptosis through a caspase-8/AIF mediated cytochrome c-independent pathway. J Nanobiotechnol. 7:22009. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Yang Y, Li X, Wang L, Han S, Zhang Y, Pratheeshkumar P, Wang X, Lu J, Yin Y, Sun L, Sun L, et al: Anti-apoptotic proteins and catalase-dependent apoptosis resistance in nickel chloride-transformed human lung epithelial cells. Int J Oncol 43: 936-946, 2013.
APA
Yang, Y., Li, X., Wang, L., Han, S., Zhang, Y., Pratheeshkumar, P. ... Ding, S. (2013). Anti-apoptotic proteins and catalase-dependent apoptosis resistance in nickel chloride-transformed human lung epithelial cells. International Journal of Oncology, 43, 936-946. https://doi.org/10.3892/ijo.2013.2004
MLA
Yang, Y., Li, X., Wang, L., Han, S., Zhang, Y., Pratheeshkumar, P., Wang, X., Lu, J., Yin, Y., Sun, L., Budhraja, A., Hitron, A. J., Ding, S."Anti-apoptotic proteins and catalase-dependent apoptosis resistance in nickel chloride-transformed human lung epithelial cells". International Journal of Oncology 43.3 (2013): 936-946.
Chicago
Yang, Y., Li, X., Wang, L., Han, S., Zhang, Y., Pratheeshkumar, P., Wang, X., Lu, J., Yin, Y., Sun, L., Budhraja, A., Hitron, A. J., Ding, S."Anti-apoptotic proteins and catalase-dependent apoptosis resistance in nickel chloride-transformed human lung epithelial cells". International Journal of Oncology 43, no. 3 (2013): 936-946. https://doi.org/10.3892/ijo.2013.2004
Copy and paste a formatted citation
x
Spandidos Publications style
Yang Y, Li X, Wang L, Han S, Zhang Y, Pratheeshkumar P, Wang X, Lu J, Yin Y, Sun L, Sun L, et al: Anti-apoptotic proteins and catalase-dependent apoptosis resistance in nickel chloride-transformed human lung epithelial cells. Int J Oncol 43: 936-946, 2013.
APA
Yang, Y., Li, X., Wang, L., Han, S., Zhang, Y., Pratheeshkumar, P. ... Ding, S. (2013). Anti-apoptotic proteins and catalase-dependent apoptosis resistance in nickel chloride-transformed human lung epithelial cells. International Journal of Oncology, 43, 936-946. https://doi.org/10.3892/ijo.2013.2004
MLA
Yang, Y., Li, X., Wang, L., Han, S., Zhang, Y., Pratheeshkumar, P., Wang, X., Lu, J., Yin, Y., Sun, L., Budhraja, A., Hitron, A. J., Ding, S."Anti-apoptotic proteins and catalase-dependent apoptosis resistance in nickel chloride-transformed human lung epithelial cells". International Journal of Oncology 43.3 (2013): 936-946.
Chicago
Yang, Y., Li, X., Wang, L., Han, S., Zhang, Y., Pratheeshkumar, P., Wang, X., Lu, J., Yin, Y., Sun, L., Budhraja, A., Hitron, A. J., Ding, S."Anti-apoptotic proteins and catalase-dependent apoptosis resistance in nickel chloride-transformed human lung epithelial cells". International Journal of Oncology 43, no. 3 (2013): 936-946. https://doi.org/10.3892/ijo.2013.2004
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team